Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization.

ABSTRACT:

Background

Peanut sublingual immunotherapy (SLIT) for 1 year has been shown to induce modest clinical desensitization in allergic children. Studies of oral immunotherapy, epicutaneous immunotherapy, and SLIT have suggested additional benefit with extended treatment.

Objective

We sought to investigate the safety, clinical effectiveness, and immunologic changes with long-term SLIT in children with peanut allergy.

Methods

Children with peanut allergy aged 1 to 11 years underwent extended maintenance SLIT with 2 mg/d peanut protein for up to 5 years. Subjects with peanut skin test wheals of less than 5 mm and peanut-specific IgE levels of less than 15 kU/L were allowed to discontinue therapy early. Desensitization was assessed through a double-blind, placebo-controlled fo

SUBMITTER: Kim EH 

PROVIDER: S-EPMC6842439 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature